Iloprost Ratiopharm

Iloprost, the active ingredient in Iloprost Ratiopharm, is a prostacyclin analog presented as a solution for injection for intravenous and subcutaneous use. It treats pulmonary arterial hypertension and related vascular conditions in adult patients.

GNH USA supplies Iloprost Ratiopharm as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Iloprost is indicated for several vascular disorders where prostacyclin pathway modulation improves blood flow.

Pulmonary arterial hypertension: improves exercise capacity and hemodynamic parameters. Digital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces new ulcer formation. Peripheral arterial disease: enhances limb perfusion and alleviates ischemic pain.

Common Side Effects: - Flushing - Headache - Nausea - Infusion site pain

Serious or Rare Side Effects: - Severe hypotension - Pulmonary edema - Bleeding complications

Precautions should be observed when initiating Iloprost therapy. - Monitor blood pressure: check regularly during and after infusion. - Assess bleeding risk: evaluate platelet function and concurrent anticoagulant use. - Evaluate renal and hepatic function: adjust therapy if significant impairment is present. - Avoid use in uncontrolled hypertension: ensure blood pressure is stable before starting. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iloprost may interact with several drug classes.

Major Interactions (Avoid): - Concomitant potent vasodilators (e.g., nitroglycerin): risk of severe hypotension. - Anticoagulants (e.g., warfarin): increased bleeding tendency. - Endothelin receptor antagonists: additive vasodilatory effect.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs: may affect renal function. - Calcium channel blockers: may enhance hypotensive response. - Beta‑blockers: may mask tachycardia associated with hypotension.